Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299178 | PMC |
| http://dx.doi.org/10.4021/jocmr2010.02.258w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).
Leuk Lymphoma
January 2025
Unit of Hematology, Azienda Ospedaliera Universitaria Senese and University of Siena, Siena, Italy.
Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation.
View Article and Find Full Text PDFPrognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma.
Front Oncol
January 2025
Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Objective: Patients with hematological malignancies have an elevated risk of developing pneumonia after contracting COVID-19. Lymphoma is the most prevalent hematologic malignancy. It is critical to identify patients at high risk of contracting COVID-19-associated pneumonia.
View Article and Find Full Text PDFPrimary large B-cell lymphoma of the central nervous system misdiagnosed as autoimmune encephalitis: a case report.
Front Oncol
January 2025
Department of 2ndBrain Center and Stroke Center, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
Primary central nervous system lymphomas (PCNSL) are rare, constituting 2 - 3% of intracranial malignancies. A 49-year-old male presented with a 20-day history of dizziness and a 15-day history of right-sided weakness. Physical examination revealed various abnormal signs.
View Article and Find Full Text PDFRegulation and therapy: the role of ferroptosis in DLBCL.
Front Pharmacol
January 2025
Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin's lymphoma (NHL), up to 30%-40% of patients will relapse and 10%-15% of patients have primary refractory disease, so exploring new treatment options is necessary. Ferroptosis is a non-apoptotic cell death mode discovered in recent years. Its occurrence pathway plays an essential impact on the therapeutic effect of tumors.
View Article and Find Full Text PDFManagement of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.
J Med Case Rep
January 2025
Director of Hospital Pharmacy, Santa Croce e Carle Hospital, Cuneo, Italy.
Background: Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton's tyrosine kinase inhibitors proving effective but not curative. Post-Bruton's tyrosine kinase inhibitor failure, the prognosis remains unfavorable.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!